Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
- PMID: 24577245
- PMCID: PMC4285461
- DOI: 10.1176/appi.ajp.2013.13070864
Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
Abstract
Objective: Chromosome 22q11.2 deletion syndrome is a neurogenetic disorder associated with high rates of schizophrenia and other psychiatric conditions. The authors report what is to their knowledge the first large-scale collaborative study of rates and sex distributions of psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome. The associations among psychopathology, intellect, and functioning were examined in a subgroup of participants.
Method: The 1,402 participants with 22q11.2 deletion syndrome, ages 6–68 years, were assessed for psychiatric disorders with validated diagnostic instruments. Data on intelligence and adaptive functioning were available for 183 participants ages 6 to 24 years.
Results: Attention deficit hyperactivity disorder (ADHD) was the most frequent disorder in children (37.10%) and was overrepresented in males. Anxiety disorders were more prevalent than mood disorders at all ages, but especially in children and adolescents. Anxiety and unipolar mood disorders were overrepresented in females. Psychotic disorders were present in 41% of adults over age 25. Males did not predominate in psychotic or autism spectrum disorders. Hierarchical regressions in the subgroup revealed that daily living skills were predicted by the presence of anxiety disorders. Psychopathology was not associated with communication or socialization skills.
Conclusions: To the authors’ knowledge, this is the largest study of psychiatric morbidity in 22q11.2 deletion syndrome. It validates previous findings that this condition is one of the strongest risk factors for psychosis. Anxiety and developmental disorders were also prevalent. These results highlight the need to monitor and reduce the long-term burden of psychopathology in 22q11.2 deletion syndrome.
Figures


References
-
- Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, Marino B, Oskarsdottir S, Philip N, Sullivan K, Swillen A, Vorstman J. International 22q11.2 Deletion Syndrome Consortium: Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr. 2011;159:332–339. e1. - PMC - PubMed
-
- Duijff SN, Klaassen PWJ, de Veye HFNS, Beemer FA, Sinnema G, Vorstman JAS. Cognitive development in children with 22q11.2 deletion syndrome. Br J Psychiatry. 2012;200:462–468. - PubMed
-
- Swillen A, Vandeputte L, Cracco J, Maes B, Ghesquière P, Devriendt K, Fryns JP. Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): evidence for a nonverbal learning disability? Child Neuropsychol. 1999;5:230–241. - PubMed
-
- De Smedt B, Devriendt K, Fryns JP, Vogels A, Gewillig M, Swillen A. Intellectual abilities in a large sample of children with velo-cardio-facial syndrome: an update. J Intellect Disabil Res. 2007;51:666–670. - PubMed
-
- Evers LJ, De Die-Smulders CE, Smeets EE, Clerkx MG, Curfs LM. The velo-cardio-facial syndrome: the spectrum of psychiatric problems and cognitive deterioration at adult age. Genet Couns. 2009;20:307–315. - PubMed
Publication types
MeSH terms
Grants and funding
- MH-087626/MH/NIMH NIH HHS/United States
- U01 MH087626/MH/NIMH NIH HHS/United States
- MH-091314/MH/NIMH NIH HHS/United States
- R01 MH085953/MH/NIMH NIH HHS/United States
- MOP-89066/CAPMC/ CIHR/Canada
- R01 HD042974/HD/NICHD NIH HHS/United States
- R01 MH064824/MH/NIMH NIH HHS/United States
- MOP-97800/CAPMC/ CIHR/Canada
- P50 HD055784/HD/NICHD NIH HHS/United States
- R01 MH078015/MH/NIMH NIH HHS/United States
- R01 HD-042974/HD/NICHD NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- MH-087636/MH/NIMH NIH HHS/United States
- R01 MH-085953/MH/NIMH NIH HHS/United States
- P50 HD-055784/HD/NICHD NIH HHS/United States
- U01 MH101722/MH/NIMH NIH HHS/United States
- U01 MH101720/MH/NIMH NIH HHS/United States
- R34 MH091314/MH/NIMH NIH HHS/United States
- U01 MH101719/MH/NIMH NIH HHS/United States
- GR067869MF/WT_/Wellcome Trust/United Kingdom
- MH-064824/MH/NIMH NIH HHS/United States
- U01 MH101724/MH/NIMH NIH HHS/United States
- MH-78015/MH/NIMH NIH HHS/United States
- U01 MH101723/MH/NIMH NIH HHS/United States
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
- HD-070454/HD/NICHD NIH HHS/United States
- MOP-74631/CAPMC/ CIHR/Canada
- U01 MH087636/MH/NIMH NIH HHS/United States
- P01 HD070454/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical